MedTrace Logo

Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

NCT01018875 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 242

Last updated 2018-06-06

No results posted yet for this study

Summary

Efficacy and safety study of ABT-288 in adults with mild-to-moderate Alzheimer's disease.

Conditions

Interventions

DRUG

ABT-288

Subjects will take 4 capsules once daily for 12 weeks.

DRUG

donepezil

Subjects will take 4 capsules once daily for 12 weeks.

DRUG

placebo

Subjects will take 4 capsules once daily for 12 weeks.

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • George Haig · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018875 on ClinicalTrials.gov